Oneness is committed to the development of new drug for the global unmet medical needs. With the global vision in innovation, we screen new drugs and initiate an in-depth exploration into the drug mechanism and pathology. The in-house research and development technology has been established to compete with international pharmaceutical companies and to maximize the value by our science and innovation.


Our culture is established on the basis of integrity to seek the truth. This is also a key foundation of our corporate governance, drug development, production, sales, and social responsibility. All of our employees work with a spirit of honesty and in compliance with regulations for an active implementation and promotion of the plans.


The biotech industry is featured with professionalism. In order to provide the investors with a better understanding of Oneness, we implemented transparency by holding an investor conference every quarter, providing response to questions on a daily basis and updating the ESG report annually. Oneness received an ESG rating by the MSCI in 2021 and scored the highest in product safety.


Focus in chronic dermatological and immunological disorders

In Progress
Research Code Therapeutic Area Indication Pre-Clinical Phase I Phase II Phase III NDA Market More
  • ON101 (FESPIXON®)
    Diabetic Foot Ulcer

    ON101 is a first-in-class new drug targeting the subsets of macrophages to promote healing of the chronic wounds. It has been demonstrated with the superior efficacy to the standard care dressing in a Phase 3 MRCT completed in the US, Taiwan, and China. It has been marketed under the trade name FESPIXON® in Taiwan since June 2021 and been granted the Fast Track designation by the US FDA in March 2021. Multiple NDA submissions of ON101 to Asian health authorities are underway

  • FB825
    Atopic Dermatitis
    Allergic Asthma

    FB825 is a first-in-class antibody targeting IgE B cells for the treatment of allergic diseases. It specifically binds to the CεmX domain on the membrane-bound IgE B cells and induces the apoptosis and ADCC of the targeted cells

  • FB704A
    Severe Asthma
    Chronic Kidney Disease

    FB704A is an innovative monoclonal antibody drug that neutralizes IL-6. By inhibiting both the classical and trans-signaling pathways of IL-6, it explores the improvement of symptoms in severe neutrophilic asthma.

  • OB318
    Cancer (e.g., liver cancer)

    OB318 is a new drug for hepatocellular carcinoma (HCC) which is the most common type of liver cancers, accounting for 90% of the cases

  • FB918

    FB918 is a first-in-class antibody targeting the interleukin 33 (IL-33) for asthma. It has been discovered and developed from Oneness-owned antibody library

  • SNS812

    SNS812 is a first-in-class siRNA new drug for COVID-19 infection. It specifically targets the highly conserved region of SARS-COV-2 genome to inhibit virus replication and eliminate viruses in cells.           

Join Us

As one of the fastest growing companies of the biotech industry, Oneness Biotech welcomes talents who endeavor to pursue integrity, responsibility, innovation and world vision to join us.
We hope to fulfill the corporate mission of “New Drug Innovation and Care for Life” jointly with our colleagues.
We aim to establish a friendly and inspiring environment of work where our colleagues are able to increase their value along with their career.
We believe the corporate sustainability, continual expansion and talent development are the cornerstones of the future success.

More Information


要下載瀏覽器,請直接點擊以下: IE瀏覽器現已不支援大多數網站,並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

  1. 開啟新分頁(紅色框)
  2. 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
  3. 點擊【立即啟動】(藍框處)打開 Microsoft Edge
    啟動Microsoft Edge